Valuation: Mendus AB

Market Cap 279M 27.73M 25.13M 23.24M 20.97M 39.52M 2.61B 40.91M 111M 1.4B 104M 102M 4.43B P/E 2026 *
-3.01x
P/E 2027 * -4.4x
Enterprise Value 254M 25.23M 22.86M 21.15M 19.08M 35.96M 2.38B 37.22M 101M 1.27B 94.68M 92.67M 4.03B EV / Sales 2026 *
22.2x
EV / Sales 2027 * 0.55x
Free-Float
35.25%
Yield 2026 *
-
Yield 2027 * -
1 day-3.01%
1 week-18.75%
Current month-20.82%
1 month-20.09%
3 months-36.88%
6 months-27.17%
Current year-22.23%
1 week 4.36
Extreme 4.355
6.27
1 month 4.36
Extreme 4.355
6.27
Current year 3.86
Extreme 3.86
8.49
1 year 3.86
Extreme 3.86
8.49
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 54 16/03/2021
Director of Finance/CFO 60 28/02/2021
Chief Tech/Sci/R&D Officer - 05/05/2025
Director TitleAgeSince
Director/Board Member 64 01/01/2020
Director/Board Member 74 01/01/2013
Director/Board Member 50 22/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
28/2/22 Buy

Chief Technology Officer

10,000 0.0050%
24/2/22 Buy

Chief Financial Officer

10,000 0.0050%
24/2/22 Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
-3.01%-18.75%-24.78%-65.44% 27.73M
-2.69%-0.48%+53.97%+70.99% 66.33B
-0.92%+7.67%+12.64%+92.55% 60.62B
0.00%+0.39%+22.34%+90.83% 55.5B
+0.14%+2.35%+13.86%+106.64% 47.58B
-2.21%-2.47%+20.18%+32.24% 43.69B
-2.30%-10.40%+154.30%+725.54% 37.27B
+2.15%+1.42%+14.58%+54.23% 36.57B
-2.32%-2.24%+76.50%+54.55% 32.22B
+2.62%+5.90%-37.29%+393.72% 26.58B
Average -0.85%-1.83%+30.63%+155.59% 41B
Weighted average by Cap. -0.83%+0.20%+36.62%+155.23%

Financials

2026 *2027 *
Net sales 11.45M 1.14M 1.03M 953K 860K 1.62M 107M 1.68M 4.54M 57.28M 4.27M 4.18M 182M 191M 19M 17.22M 15.93M 14.37M 27.08M 1.79B 28.04M 75.87M 957M 71.32M 69.8M 3.04B
Net income -96.07M -9.54M -8.65M -8M -7.22M -13.6M -900M -14.08M -38.09M -481M -35.8M -35.04M -1.53B -66.14M -6.57M -5.95M -5.51M -4.97M -9.36M -619M -9.69M -26.23M -331M -24.65M -24.13M -1.05B
Net Debt -25.19M -2.5M -2.27M -2.1M -1.89M -3.57M -236M -3.69M -9.99M -126M -9.39M -9.19M -400M -174M -17.3M -15.68M -14.5M -13.08M -24.65M -1.63B -25.52M -69.07M -871M -64.92M -63.54M -2.77B
Projected Income Statement - Annual - Mendus AB
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
13/11/26 SEK 4.355 -3.01% 29,286
12/11/26 SEK 4.490 -8.37% 189,246
11/11/26 SEK 4.900 -1.51% 85,340
10/11/26 SEK 4.975 -15.39% 111,152
09/11/26 SEK 5.880 +9.70% 16,294
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Mendus AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.355SEK
Average target price
33.45SEK
Spread / Average Target
+668.08%
  1. Stock Market
  2. Stocks
  3. IMMU Stock